Reduced telomere length in amniocytes: an early biomarker of abnormal fetal development?


Journal

Human molecular genetics
ISSN: 1460-2083
Titre abrégé: Hum Mol Genet
Pays: England
ID NLM: 9208958

Informations de publication

Date de publication:
23 08 2022
Historique:
received: 10 12 2021
revised: 14 02 2022
accepted: 01 03 2022
pubmed: 5 3 2022
medline: 27 8 2022
entrez: 4 3 2022
Statut: ppublish

Résumé

Telomeres protect chromosome ends and control cell division and senescence. During organogenesis, telomeres need to be long enough to ensure the cell proliferation necessary at this stage of development. Previous studies have shown that telomere shortening is associated with growth retardation and congenital malformations. However, these studies were performed in newborns or postnatally, and data on telomere length (TL) during the prenatal period are still very limited. We measured TL using quantitative PCR in amniotic fluid (AF) and chorionic villi (CV) samples from 69 control fetuses with normal ultrasound (52 AF and 17 CV) and 213 fetuses (165 AF and 48 CV) with intrauterine growth retardation (IUGR) or congenital malformations diagnosed by ultrasound. The samples were collected by amniocentesis at the gestational age (GA) of 25.0 ± 5.4 weeks and by CV biopsy at 18.1 ± 6.3 weeks. In neither sample type was TL influenced by GA or fetal sex. In AF, a comparison of abnormal versus normal fetuses showed a significant telomere shortening in cases of IUGR (reduction of 34%, P < 10-6), single (29%, P < 10-6) and multiple (44%, P < 10-6) malformations. Similar TL shortening was also observed in CV from abnormal fetuses but to a lesser extent (25%, P = 0.0002; 18%, P = 0.016; 20%, P = 0.004, respectively). Telomere shortening was more pronounced in cases of multiple congenital anomalies than in fetuses with a single malformation, suggesting a correlation between TL and the severity of fetal phenotype. Thus, TL measurement in fetal samples during pregnancy could provide a novel predictive marker of pathological development.

Identifiants

pubmed: 35244708
pii: 6542340
doi: 10.1093/hmg/ddac054
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2669-2677

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Auteurs

Carole Goumy (C)

Cytogénétique Médicale, CHU Clermont-Ferrand, CHU Estaing, F-63000 Clermont-Ferrand, France.
INSERM U1240 Imagerie Moléculaire et Stratégies Théranostiques, Université Clermont Auvergne, Clermont-Ferrand, France.

Lauren Veronese (L)

Cytogénétique Médicale, CHU Clermont-Ferrand, CHU Estaing, F-63000 Clermont-Ferrand, France.
EA7453 CHELTER « Clonal Heterogeneity, Leukemic environment, Therapy Resistance of Chronic Leukemias », Université Clermont Auvergne, Clermont Ferrand, France.

Rodrigue Stamm (R)

Cytogénétique Médicale, CHU Clermont-Ferrand, CHU Estaing, F-63000 Clermont-Ferrand, France.

Quentin Domas (Q)

Cytogénétique Médicale, CHU Clermont-Ferrand, CHU Estaing, F-63000 Clermont-Ferrand, France.

Kamil Hadjab (K)

Cytogénétique Médicale, CHU Clermont-Ferrand, CHU Estaing, F-63000 Clermont-Ferrand, France.

Denis Gallot (D)

Unité de Médecine Fœtale, CHU Clermont-Ferrand, CHU Estaing, F-63000 Clermont Ferrand, France.

Hélène Laurichesse (H)

Unité de Médecine Fœtale, CHU Clermont-Ferrand, CHU Estaing, F-63000 Clermont Ferrand, France.

Amélie Delabaere (A)

Unité de Médecine Fœtale, CHU Clermont-Ferrand, CHU Estaing, F-63000 Clermont Ferrand, France.

Laetitia Gouas (L)

Cytogénétique Médicale, CHU Clermont-Ferrand, CHU Estaing, F-63000 Clermont-Ferrand, France.
INSERM U1240 Imagerie Moléculaire et Stratégies Théranostiques, Université Clermont Auvergne, Clermont-Ferrand, France.

Gaelle Salaun (G)

Cytogénétique Médicale, CHU Clermont-Ferrand, CHU Estaing, F-63000 Clermont-Ferrand, France.
INSERM U1240 Imagerie Moléculaire et Stratégies Théranostiques, Université Clermont Auvergne, Clermont-Ferrand, France.

Céline Perbel-Richard (C)

Cytogénétique Médicale, CHU Clermont-Ferrand, CHU Estaing, F-63000 Clermont-Ferrand, France.

Philippe Vago (P)

Cytogénétique Médicale, CHU Clermont-Ferrand, CHU Estaing, F-63000 Clermont-Ferrand, France.
INSERM U1240 Imagerie Moléculaire et Stratégies Théranostiques, Université Clermont Auvergne, Clermont-Ferrand, France.

Andrei Tchirkov (A)

Cytogénétique Médicale, CHU Clermont-Ferrand, CHU Estaing, F-63000 Clermont-Ferrand, France.
EA7453 CHELTER « Clonal Heterogeneity, Leukemic environment, Therapy Resistance of Chronic Leukemias », Université Clermont Auvergne, Clermont Ferrand, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH